Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRCH: Obeldesivir for High-Risk COVID-19
NCT05603143Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Obeldesivir with Placebo (2 arms). Primary endpoint: Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death at Day 29. Started Nov 2022; status: terminated.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05603143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603143.